[ad_1]
About 1 in 200 (0.5%) reports of vaccine complaints in Lithuania increased in February, as the proportion of complainants reached 0.3% at the beginning of last month.
The number of complaints increased in February
729 notifications were received for Pfizer, 61 for Moderna, and 401 for AstraZeneca.
G. Anddrulionis revealed that the majority of vaccinated people complain about the effect of the AstraZeneca vaccine. A suspected reaction to this vaccine was reported in 12.9 out of every 1000 vaccinated people. For Pfizer and Moderna 3.8 and 4.9 respectively.
In February alone, there were 890 reports of suspected adverse reactions.
“Unfortunately, we also have deaths in the group of registered vaccinated people. To date, we have 2 registered deaths, ”said G. Andrdrionis and assured that none of the deaths is related to vaccination.
“These are the deaths of the elderly, a vulnerable group, but they have nothing to do with vaccination,” he added.
868 notifications filed in February were classified as mild to moderate and only 22 as severe.
People of all ages from the age of 19 have complained about the effects of the vaccine. up to 87 years
The most common complaints are fever, headache, muscle aches, nausea.
Good news about the AstraZeneca vaccine
Rugilė Pilvinienė, Senior Advisor to IWT’s Pharmacovigilance and Poisoning Information Division, emphasized that none of the three vaccines used in Lithuania contain the COVID-19 virus, therefore the vaccine cannot cause a coronavirus infection.
“Therefore, any case of illness that occurs after the second dose of the vaccine and at the appropriate time during which immunity should develop is simply a case of illness that may indicate a lack of immunity or ineffectiveness of the vaccine. , but that he cannot scale the idea of vaccination, “explained R.Pilvinienė.
He stressed that the side effects of the three vaccines are very similar.
The difference is that Moderna and Pfizer vaccines, based on their description, are more likely to cause an adverse reaction after the second dose, while AstraZeneca is more likely to cause an adverse reaction after the first.
“It is likely that after the second AstraZeneca, all the outages that they are now complaining about will not be alleviated, or will be alleviated. As we can see from the content of the reports, some people have been so scared (…) by the intimidation of the side effects that have occurred so actively.
But according to the drug information documents, which we trust, we still have to believe that after the second dose, there will be fewer and easier reactions, ”said R. Pilvinienė.
The specialist pointed out that a large proportion of people who complain about the vaccine are seen in younger groups of working age. It is associated with greater social activity, computer literacy and the peculiarities of vaccines.
“It just came to our knowledge then. This is stated in the Summary of Product Characteristics. The ability of all three vaccines to cause those common side effects that indicate our body responds to the vaccine is greater in younger people.” R. Pilvinienė explained.
Late last week, IWT reported one death after vaccination. A 77-year-old person has died, the death is not related to the vaccine. The health center of the person who vaccinates has reported a suspected adverse reaction to the vaccine
Gytis Andrulionis, the head of the IWT, later emphasized that the medical institution did not link the death to the vaccine, and IWT has no reason to doubt it.
“But since that death occurred immediately after the vaccination, in minutes, we felt the need to report it so that there is no speculation,” the IWT head explained during a press conference.
Lrytas.lt remember that the COVID-19 vaccine does not start working right away. A second dose of the vaccine is always needed. Immunity develops over time. The Ministry of Health (SAM) has emphasized that immunity to the COVID-19 disease develops only after two doses of the full vaccination schedule and at least one week after the second dose of the vaccine.
The SAM recalls that, based on the results of clinical trials of the vaccine and general immunological principles, specific immunity to COVID-19 disease develops only after a full vaccination schedule and at least one week after the second dose of the vaccine.
